Modified-release, enteric-coated and other special formulations explained

Tablets and capsules may look like simple, uniform objects, but many are highly engineered delivery systems. The physical design of a medicine—its formulation—determines how quickly and where in the body the active ingredient is released. While standard medicines release their active ingredients immediately after ingestion, others are designed to release them slowly over time or only after passing through the stomach. These are known as modified-release formulations. They are developed to maintain steady medicine levels in the blood, reduce side effects, and allow patients to take their medicines less frequently.

Understanding the acronyms (SR, XR, and ER)

When reading medicine packaging, you will often see letters such as SR, XR, ER, or CR appended to a drug's name. These stand for 'sustained release', 'extended release', 'controlled release', and 'prolonged release'. While the exact terminology can vary depending on the manufacturer, they generally describe the same concept: the active ingredient is formulated to dissolve slowly over an extended period. For example, a medicine that needs to be taken four times a day in an immediate-release form might only need to be taken once a day as an extended-release formulation.

Standard, immediate-release formulations typically deliver the drug quickly, causing a sharp peak in blood concentration that gradually falls until the next dose is needed. Modified-release formulations flatten this curve. By slowing the release of the drug, they prevent the high peaks that can cause toxicity and avoid the low troughs that can leave the patient under-medicated. This is often achieved by embedding the drug in a polymer matrix or using a special membrane that limits how quickly the body absorbs the medicine.

Enteric coatings and stomach acid protection

Another distinct type of special formulation is the enteric-coated tablet. The term 'enteric' refers to the intestine. An enteric coating is a chemical barrier applied to the outside of a tablet that prevents it from dissolving in the highly acidic environment of the stomach. These coatings are typically made from polymers that remain intact in acidic environments but readily dissolve when exposed to the higher pH of the upper intestine.

There are two primary reasons for using enteric coatings. First, some active ingredients are unstable in acid and would be destroyed by stomach acid before they can be absorbed. Second, some medicines can irritate the stomach lining, potentially causing ulcers or severe discomfort. The enteric coating ensures the tablet passes through the stomach intact and only dissolves once it reaches the small intestine, protecting both the drug and the stomach.

Why crushing or splitting is dangerous

The safety and effectiveness of modified-release and enteric-coated formulations rely entirely on their physical structure. When a tablet is designed to release medicine over 24 hours, the active ingredient is carefully distributed throughout a specific matrix or encapsulated behind a rate-controlling membrane. If a patient crushes, chews, or splits one of these tablets, they destroy the very mechanism that controls the release.

For modified-release formulations, breaking the tablet can cause 'dose dumping'—a dangerous event where the entire 24-hour dose is released into the bloodstream all at once, potentially leading to a toxic overdose. For enteric-coated tablets, crushing them exposes the stomach to the irritant drug directly or allows stomach acid to destroy the medicine. Some tablets feature a score line, indicating they are designed to be split safely to deliver a smaller dose. However, modified-release and enteric-coated tablets almost never have these score lines. If a patient has difficulty swallowing whole tablets, a healthcare professional should be consulted to identify an alternative formulation, such as a liquid or a standard immediate-release tablet that is safe to crush.

Formulation changes and medicine registration

Because the technology behind modified-release formulations is complex, moving from an immediate-release version to a modified-release one—or switching between different brands of modified-release medicines—is not a simple substitution. Regulators like the South African Health Products Regulatory Authority (SAHPRA) require bioequivalence studies to demonstrate that a generic modified-release product delivers the drug at the same rate and to the same extent as the original product. Switching a patient from one modified-release formulation to another can alter how the body processes the drug, making medical supervision essential during any changes.

These formulation differences also carry implications for pricing. In South Africa, the Single Exit Price applies to specific formulations and strengths, meaning a standard tablet and an extended-release tablet of the same active ingredient will have different pricing profiles. Patients and healthcare providers can use tools like HealthSA to search for specific formulations and verify their SAHPRA registration. Understanding what these acronyms mean helps ensure that patients use their medicines safely and that any substitution is handled with proper regulatory oversight.